Enavogliflozin Phase 3 trials to begin in China
With a green light from the Chinese National Medical Products Administration, the company will conduct the trials on patients with the type-2 diabetes. The patients will be given Enavogliflozin along with Metformin, the most commonly prescribed drug for type-2 diabetes.
Type-2 diabetes, the most common type of diabetes, is a disease that occurs when the blood glucose is too high.
Enavogliflozin helps the body excrete glucose directly into the urine, the company explained.
Daewoong aims to market the drug in the Chinese market from 2025.
Enavogliflozin has already been in trials in Korea and, where it produced meaningful results proving efficacy and safety. The company plans to sell the drug in Korea from 2023.
“The fact that China gave the approval to conduct trials of Fexuprazan, a gastroesophageal reflux treatment, the Nabota botulinum toxin and even Enavogliflozin proves that it recognizes Daewoong’s outstanding technical skills,” said Daewoong Pharmaceutical CEO Jeon Seng-ho, in Tuesday’s release.
Daewoong is currently awaiting marketing authorization for Nabota in China. It aims to introduce the product in China by the end of 2022.
BY SARAH CHEA [firstname.lastname@example.org]